Welcome to our dedicated page for Thermo Fishr Sci SEC filings (Ticker: TMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Thermo Fisher Scientific Inc. (NYSE: TMO) files a wide range of documents with the U.S. Securities and Exchange Commission, and this page aggregates those SEC filings for investors tracking TMO. The company’s common stock and multiple series of senior notes are listed on the New York Stock Exchange, and its filings describe the terms, rankings and covenants of these securities, as well as material events affecting the business.
Recent Form 8‑K filings illustrate the types of information Thermo Fisher discloses. Several 8‑Ks detail public offerings of senior notes in U.S. dollars and euros, including maturities, interest payment schedules, redemption provisions, change‑of‑control protections and the use of proceeds for general corporate purposes such as acquisitions, debt repayment or refinancing, working capital, capital expenditures or equity repurchases. Other 8‑Ks report the completion of the acquisition of Solventum Corporation’s purification and filtration business and the signing of a definitive agreement to acquire Clario Holdings, Inc.
Thermo Fisher also uses 8‑K filings to communicate quarterly financial results, leadership transitions and organizational changes. For example, filings describe announcements of financial results for specific fiscal quarters, the planned retirement of the Senior Vice President and Chief Financial Officer and the appointment of a successor, and updates to the organizational structure and leadership team, including changes in executive roles.
On Stock Titan’s SEC filings page for TMO, users can access these current reports alongside other registered securities information, and benefit from AI‑powered summaries that explain key terms, highlight significant covenants, and clarify how new debt offerings, acquisitions, leadership changes or other material events may affect Thermo Fisher Scientific’s capital structure and corporate profile.
Thermo Fisher Scientific (TMO) filed a Form 144 notice for a proposed sale of common stock by an affiliated holder. The filing lists 10,225 shares to be sold with an aggregate market value of $5,844,850.08, through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 11/07/2025.
The shares come from a mix of equity awards, including 8,475 shares from an option granted on 02/26/2019 (paid in cash on 11/07/2025) and multiple restricted stock vestings totaling 1,750 shares from 2021–2024. As context, shares outstanding were 375,708,059 at the time referenced in the notice; this is a baseline figure, not the amount being offered.
Thermo Fisher Scientific (TMO) reported Q3 2025 results. Total revenues were $11,122 million, up from $10,598 million a year ago, with product revenue at $6,489 million and service revenue at $4,633 million. Diluted EPS was $4.27 versus $4.25, and operating income reached $1,941 million.
Year to date, operating cash flow was $4,361 million versus $5,377 million in 2024, reflecting working capital outflows. The balance sheet shows cash and equivalents of $1,982 million and long-term obligations of $31,857 million. The company issued additional senior notes in October totaling $2,500 million. Remaining performance obligations were $26.46 billion, with approximately 53% expected to be recognized within 12 months.
By business in Q3: Life Sciences Solutions revenue was $2,588 million, Analytical Instruments $1,893 million, Specialty Diagnostics $1,174 million, and Laboratory Products and Biopharma Services $5,970 million. The company recorded $135 million of restructuring and other costs in Q3 ($316 million year to date) and actions in 2025 affected about 4% of its workforce. Share repurchases were $2,963 million year to date; dividends paid were $474 million.
Thermo Fisher Scientific (TMO) announced a definitive agreement to acquire Clario Holdings for approximately $8.875 billion in cash at closing, plus $125 million in deferred consideration and up to $400 million in contingent consideration. The transaction is expected to close by the middle of 2026, subject to customary closing conditions and regulatory approvals.
This deal adds a significant clinical research and data-focused asset to Thermo Fisher’s portfolio. The consideration structure mixes upfront cash with deferred and contingent payments, aligning part of the price to post‑closing outcomes. The company noted typical regulatory and integration risks and referenced risk factors in its latest periodic reports.
Thermo Fisher Scientific (TMO) disclosed a routine insider transaction on Form 4. Executive Vice President Gianluca Pettiti sold 400 shares of common stock on 10/24/2025 at $574.15 per share (transaction code S). After the sale, he beneficially owned 21,152.223 shares, held directly. The transaction was effected under a Rule 10b5-1 trading plan adopted on February 10, 2025.
Thermo Fisher Scientific (TMO) reported insider activity by Chairman & CEO Marc N. Casper. On 10/24/2025 and 10/27/2025, he exercised stock options for 17,104 and 7,250 shares, respectively, at an exercise price of $253.99 per share, and sold the same number of shares on each date in multiple transactions at weighted average prices as disclosed.
Following these transactions, his direct beneficial ownership was 113,762.285 shares. He also reported indirect holdings of 11,300 shares by the Alison Casper 2020 Irrevocable Trust, 14,608 shares by Floral Park Associates, Inc., and 5,000 shares by the MNC 2020 Irrevocable Trust. The trades were conducted under a Rule 10b5-1 trading plan adopted on April 28, 2025.
Thermo Fisher Scientific (TMO): Form 144 notice of proposed sale. A holder filed to sell 7,250 shares of common stock, showing an aggregate market value of $4,104,237.84. The approximate sale date is 10/27/2025, with the shares listed on the NYSE. The filing lists 377,612,121 shares outstanding. The broker named is Fidelity Brokerage Services LLC.
The shares to be sold were acquired on 10/27/2025 via an option originally granted on 02/26/2019, with payment stated as cash. The notice also reports recent sales by Marc N. Casper, including 10,000 shares on 08/06/2025 for $4,518,207.00 and 17,104 shares on 10/24/2025 for $9,809,820.07.
TMO: A stockholder filed a Form 144 notice to sell up to 17,104 common shares with an aggregate market value of $980,820.29. The notice lists Fidelity Brokerage Services LLC as broker, an approximate sale date of 10/24/2025, and trading on the NYSE.
The filing shows these shares were acquired on 10/24/2025 via an option granted on 02/26/2019, with payment noted as cash. As context, 377,612,121 shares were outstanding.
Recent activity reported by the same seller over the past three months includes 10,000 shares on 08/06/2025 for $4,518,207.00 and 8,000 shares on 08/07/2025 for $3,635,549.60, among other smaller transactions.
Thermo Fisher Scientific (TMO) filed a Form 144 notice for a proposed sale of 400 common shares on or about 10/24/2025 through Fidelity Brokerage Services LLC on the NYSE. The filing lists an aggregate market value of
The shares to be sold were acquired via restricted stock vesting on 02/28/2024 (87 shares), 05/05/2024 (125 shares), and 08/23/2024 (188 shares). In the past three months, Gianluca Pettiti sold 400 shares on 07/25/2025 for
The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.
Thermo Fisher Scientific (TMO) furnished an update on its financial results by filing an Item 2.02 Form 8‑K. The company announced results for the fiscal quarter ended September 27, 2025 and provided the full details in a press release furnished as Exhibit 99.1.
The information is furnished and not deemed filed under Section 18 of the Exchange Act. Additional materials include the Cover Page Interactive Data File (Exhibit 104).
Thermo Fisher Scientific sold a new series of notes under an underwriting agreement entered on
The company intends to use the net proceeds for general corporate purposes, which may include acquisitions, repayment and refinancing of debt, working capital, capital expenditures, repurchases of equity securities, or temporary investment in short-term liquid instruments. The Underwriting Agreement is filed as Exhibit 1.1; a Twenty-Ninth Supplemental Indenture is filed as Exhibit 4.2, and a legal opinion and consent from its counsel are filed as Exhibit 5.1/23.1.
FAQ
What is the current stock price of Thermo Fishr Sci (TMO)?
What is the market cap of Thermo Fishr Sci (TMO)?
